DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: ELIQUIS

Summary for Tradename: ELIQUIS

Patents:2
Applicants:1
NDAs:1
Suppliers: see list1
drug
patent expirations by year for
 ELIQUIS

Pharmacology for Tradename: ELIQUIS

Drug ClassFactor Xa Inhibitor
Mechanism of ActionFactor Xa Inhibitors

Clinical Trials for: ELIQUIS

Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
Status: Completed Condition: Healthy Subjects

Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects
Status: Completed Condition: Healthy Volunteers

Bioavailability of Apixaban Crushed Tablet
Status: Completed Condition: Thrombosis

Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)
Status: Recruiting Condition: Non-valvular Atrial Fibrillation

Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects
Status: Completed Condition: Healthy Volunteers

Early Post-marketing Study of Eliquis (Apixaban)
Status: Not yet recruiting Condition: Non-valvular Atrial Fibrillation (NVAF)

BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
Status: Completed Condition: Venous Thrombosis; Pulmonary Embolism

Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis
Status: Completed Condition: End Stage Renal Disease

Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events
Status: Not yet recruiting Condition: Ischemic Stroke; TIA

Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic Disorder
Status: Recruiting Condition: Thromboembolism

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155Dec 28, 2012RXNo<disabled><disabled>
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155Dec 28, 2012RXNo<disabled><disabled>
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155Dec 28, 2012RXNo6,413,980<disabled>YY<disabled>
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155Dec 28, 2012RXNo6,967,208<disabled>YY<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc